Functional cooperation between co-amplified genes promotes aggressive phenotypes of HER2-positive breast cancer

[1]  Xiaoting Zhang,et al.  Estrogen Receptor-Mediated Gene Transcription and Cistrome , 2018, Estrogen Receptor and Breast Cancer.

[2]  Xiaoting Zhang,et al.  HER2-Driven Breast Tumorigenesis Relies upon Interactions of the Estrogen Receptor with Coactivator MED1. , 2018, Cancer research.

[3]  W. Chiu,et al.  Structural and Functional Impacts of ER Coactivator Sequential Recruitment. , 2017, Molecular cell.

[4]  F. Cognetti,et al.  First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces? , 2016, Journal of experimental & clinical cancer research : CR.

[5]  Michael D. Brooks,et al.  Therapeutic Implications of Cellular Heterogeneity and Plasticity in Breast Cancer. , 2015, Cell stem cell.

[6]  S. Cosimo,et al.  Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  M. Wicha,et al.  Distinct FAK activities determine progenitor and mammary stem cell characteristics. , 2013, Cancer research.

[8]  K. Nephew,et al.  Silencing MED1 Sensitizes Breast Cancer Cells to Pure Anti-Estrogen Fulvestrant In Vitro and In Vivo , 2013, PloS one.

[9]  A. Børresen-Dale,et al.  The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells , 2013, Molecular oncology.

[10]  J. Baselga,et al.  Dual human epidermal growth factor receptor 2 (HER2) blockade and hormonal therapy for the treatment of primary HER2-positive breast cancer: one more step toward chemotherapy-free therapy. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  N. Rosenfeld,et al.  Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA , 2013, Nature.

[12]  Jia Luo,et al.  Cross-talk between HER2 and MED1 regulates tamoxifen resistance of human breast cancer cells. , 2012, Cancer research.

[13]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[14]  J. Visvader,et al.  Cancer stem cells: current status and evolving complexities. , 2012, Cell stem cell.

[15]  D. Krag,et al.  GRB7 is required for triple-negative breast cancer cell invasion and survival , 2012, Breast Cancer Research and Treatment.

[16]  J. Visvader,et al.  Isolation of Mouse Mammary Epithelial Subpopulations: A Comparison of Leading Methods , 2012, Journal of Mammary Gland Biology and Neoplasia.

[17]  L. Rydén,et al.  Med1 plays a critical role in the development of tamoxifen resistance. , 2012, Carcinogenesis.

[18]  David R. Kelley,et al.  Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks , 2012, Nature Protocols.

[19]  I. Ellis,et al.  Differential oestrogen receptor binding is associated with clinical outcome in breast cancer , 2011, Nature.

[20]  Rachel Schiff,et al.  Mechanisms of endocrine resistance in breast cancer. , 2011, Annual review of medicine.

[21]  F. Claret,et al.  JAB1/CSN5: a new player in cell cycle control and cancer , 2010, Cell Division.

[22]  F. Abdul-Karim,et al.  HER2/ErbB2-induced Breast Cancer Cell Migration and Invasion Require p120 Catenin Activation of Rac1 and Cdc42* , 2010, The Journal of Biological Chemistry.

[23]  R. Roeder,et al.  Key roles for MED1 LxxLL motifs in pubertal mammary gland development and luminal-cell differentiation , 2010, Proceedings of the National Academy of Sciences.

[24]  M. Golightly,et al.  Isolation of circulating epithelial and tumor progenitor cells with an invasive phenotype from breast cancer patients , 2010, International journal of cancer.

[25]  W. Miller,et al.  Both t-Darpp and DARPP-32 can cause resistance to trastuzumab in breast cancer cells and are frequently expressed in primary breast cancers , 2010, Breast Cancer Research and Treatment.

[26]  P. Pelicci,et al.  Biological and Molecular Heterogeneity of Breast Cancers Correlates with Their Cancer Stem Cell Content , 2010, Cell.

[27]  J. Visvader,et al.  Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. , 2009, Genes & development.

[28]  P. Rørth,et al.  Collective cell migration. , 2009, Annual review of cell and developmental biology.

[29]  Raghu Kalluri,et al.  The basics of epithelial-mesenchymal transition. , 2009, The Journal of clinical investigation.

[30]  Suimin Qiu,et al.  Stabilization of snail by NF-kappaB is required for inflammation-induced cell migration and invasion. , 2009, Cancer cell.

[31]  N. Spector,et al.  Acquired Resistance to Small Molecule ErbB2 Tyrosine Kinase Inhibitors , 2008, Clinical Cancer Research.

[32]  Max S Wicha,et al.  Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  B. O’Malley,et al.  Nuclear receptor coregulators: judges, juries, and executioners of cellular regulation. , 2007, Molecular cell.

[34]  Genee Y. Lee,et al.  Three-dimensional culture models of normal and malignant breast epithelial cells , 2007, Nature Methods.

[35]  M. Clarke,et al.  Cancer stem cells: models and concepts. , 2007, Annual review of medicine.

[36]  A. Ashworth,et al.  Dissociation of estrogen receptor expression and in vivo stem cell activity in the mammary gland , 2007, The Journal of cell biology.

[37]  R. Cardiff,et al.  Effect of c-neu/ ErbB2 expression levels on estrogen receptor alpha-dependent proliferation in mammary epithelial cells: implications for breast cancer biology. , 2006, Cancer research.

[38]  J. O’Shaughnessy,et al.  Molecular signatures predict outcomes of breast cancer. , 2006, The New England journal of medicine.

[39]  G. Hortobagyi,et al.  Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer , 2006, Nature Clinical Practice Oncology.

[40]  J. Thiery,et al.  Complex networks orchestrate epithelial–mesenchymal transitions , 2006, Nature Reviews Molecular Cell Biology.

[41]  J. Yager,et al.  Estrogen carcinogenesis in breast cancer. , 2006, The New England journal of medicine.

[42]  François Vaillant,et al.  Generation of a functional mammary gland from a single stem cell , 2006, Nature.

[43]  B. Chait,et al.  MED1/TRAP220 exists predominantly in a TRAP/ Mediator subpopulation enriched in RNA polymerase II and is required for ER-mediated transcription. , 2005, Molecular cell.

[44]  R. Schiff,et al.  Estrogen receptor positivity in mammary tumors of Wnt-1 transgenic mice is influenced by collaborating oncogenic mutations , 2005, Oncogene.

[45]  C. Osborne,et al.  HER-2 Amplification, HER-1 Expression, and Tamoxifen Response in Estrogen Receptor-Positive Metastatic Breast Cancer , 2004, Clinical Cancer Research.

[46]  M. Hung,et al.  Dysregulation of cellular signaling by HER2/neu in breast cancer. , 2003, Seminars in oncology.

[47]  R. Roeder,et al.  The eukaryotic transcriptional machinery: complexities and mechanisms unforeseen , 2003, Nature Medicine.

[48]  A. Thor,et al.  Hormonal and dietary modulation of mammary carcinogenesis in mouse mammary tumor virus-c-erbB-2 transgenic mice. , 2003, Cancer research.

[49]  S. Luoh.  Amplification and expression of genes from the 17q11∼q12 amplicon in breast cancer cells , 2002 .

[50]  T. Graubert,et al.  Sca-1(pos) cells in the mouse mammary gland represent an enriched progenitor cell population. , 2002, Developmental biology.

[51]  V. Jordan,et al.  Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention. , 2002, Trends in molecular medicine.

[52]  C. Schneeberger,et al.  Production and actions of estrogens. , 2002, The New England journal of medicine.

[53]  O. Monni,et al.  New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays. , 2001, Cancer research.

[54]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[55]  Myles Brown,et al.  Cofactor Dynamics and Sufficiency in Estrogen Receptor–Regulated Transcription , 2000, Cell.

[56]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[57]  B. O’Malley,et al.  The 26S Proteasome Is Required for Estrogen Receptor-α and Coactivator Turnover and for Efficient Estrogen Receptor-α Transactivation , 2000 .

[58]  R. Roeder,et al.  Transcriptional regulation through Mediator-like coactivators in yeast and metazoan cells. , 2000, Trends in biochemical sciences.

[59]  B. Hogan,et al.  Inhibition of mammary duct development but not alveolar outgrowth during pregnancy in transgenic mice expressing active TGF-beta 1. , 1993, Genes & development.

[60]  R. Cardiff,et al.  Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[61]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[62]  Miguel Martín,et al.  Emerging Therapeutic Options for HER2-Positive Breast Cancer. , 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[63]  Carlos L Arteaga,et al.  Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications. , 2012, Critical reviews in oncogenesis.